{"doc_id": "32862111", "type of study": "Therapy", "title": "", "abstract": "Interferon \u03b2-1b in treatment of severe COVID-19: A randomized clinical trial.\nIn this study, efficacy and safety of interferon (IFN) \u03b2-1b in the treatment of patients with severe COVID-19 were evaluated.\nAmong an open-label, randomized clinical trial, adult patients (\u226518\u00a0years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group.\nPatients in the IFN group received IFN \u03b2-1b (250 mcg subcutaneously every other day for two consecutive weeks) along with the national protocol medications while in the control group, patients received only the national protocol medications (lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7-10\u00a0days).\nThe primary outcome of the study was time to clinical improvement.\nSecondary outcomes were in-hospital complications and 28-daymortality.\nBetween April 20 and May 20, 2020, 80 patients were enrolled and finally 33 patients in each group completed the study.\nTime to clinical improvment in the IFN group was significantly shorter than the control group ([9(6-10) vs. 11(9-15) days respectively, p\u00a0=\u00a00.002, HR\u00a0=\u00a02.30; 95% CI: 1.33-3.39]).\nAt day 14, the percentage of discharged patients was 78.79% and 54.55% in the IFN and control groups respectively (OR\u00a0=\u00a03.09; 95% CI: 1.05-9.11, p\u00a0=\u00a00.03).\nICU admission rate in the control group was significantly higher than the IFN group (66.66% vs. 42.42%, p\u00a0=\u00a00.04).\nThe duration of hospitalization and ICU stay were not significantly different between the groups All-cause 28-day mortality was 6.06% and 18.18% in the IFN and control groups respectively (p\u00a0=\u00a00.12).\nIFN \u03b2-1b was effective in shortening the time to clinical improvement without serious adverse events in patients with severe COVID-19.\nFurthermore, admission in ICU and need for invasive mechanical ventilation decreased following administration of IFN \u03b2-1b.\nAlthough 28-day mortality was lower in the IFN group, further randomized clinical trials with large sample size are needed for exact estimation of survival benefit of IFN \u03b2-1b.\nCopyright \u00a9 2020 Elsevier B.V. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 47}, {"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 55}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 103}, {"term": "severe COVID-19", "negation": "negated", "UMLS": {}, "start": 118, "end": 133}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Interferon \u03b2-1b in treatment of severe COVID-19 : A randomized clinical trial .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 47}], "Intervention": [{"term": "Interferon \u03b2-1b", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In this study , efficacy and safety of interferon ( IFN ) \u03b2-1b in the treatment of patients with severe COVID-19 were evaluated .", "Evidence Elements": {"Participant": [{"term": "severe", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 103}], "Intervention": [{"term": "interferon ( IFN ) \u03b2-1b", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 62}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 24}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 35}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Among an open-label , randomized clinical trial , adult patients ( \u226518 years old ) with severe COVID-19 were randomly assigned ( 1:1 ) to the IFN group or the control group .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 55}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 103}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients in the IFN group received IFN \u03b2-1b ( 250 mcg subcutaneously every other day for two consecutive weeks ) along with the national protocol medications while in the control group , patients received only the national protocol medications ( lopinavir / ritonavir or atazanavir / ritonavir plus hydroxychloroquine for 7-10 days ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN \u03b2-1b", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 43}, {"term": "national protocol medications", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 157}, {"term": "national protocol medications", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 157}, {"term": "ritonavir", "negation": "affirmed", "UMLS": {}, "start": 258, "end": 267}, {"term": "ritonavir plus", "negation": "affirmed", "UMLS": {}, "start": 284, "end": 298}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The primary outcome of the study was time to clinical improvement .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "time to clinical improvement", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 65}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary outcomes were in-hospital complications and 28-daymortality .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "in-hospital complications", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 49}, {"term": "28-daymortality", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 69}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Between April 20 and May 20, 2020 , 80 patients were enrolled and finally 33 patients in each group completed the study .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Time to clinical improvment in the IFN group was significantly shorter than the control group ( [ 9 ( 6-10 ) vs . 11 ( 9-15 ) days respectively , p = 0.002 , HR = 2.30 ; 95 % CI : 1.33-3.39 ] ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 38}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 87}], "Outcome": [{"term": "Time to clinical improvment", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 27}], "Observation": [{"term": "significantly shorter", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 70}, {"term": "9 ( 6-10 )", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 108}, {"term": "11 ( 9-15 ) days", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 130}], "Count": []}, "Evidence Propositions": [{"Intervention": ["IFN", "control"], "Observation": "significantly shorter", "Outcome": "Time to clinical improvment", "Count": ""}, {"Intervention": "IFN", "Observation": "9 ( 6-10 )", "Outcome": "Time to clinical improvment", "Count": ""}, {"Intervention": "control", "Observation": "11 ( 9-15 ) days", "Outcome": "Time to clinical improvment", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "At day 14 , the percentage of discharged patients was 78.79 % and 54.55 % in the IFN and control groups respectively ( OR = 3.09 ; 95 % CI : 1.05-9.11 , p = 0.03 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 84}, {"term": "control", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 96}], "Outcome": [{"term": "percentage of discharged patients", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 49}], "Observation": [{"term": "78.79 %", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 61}, {"term": "54.55 %", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 73}], "Count": []}, "Evidence Propositions": [{"Intervention": "IFN", "Observation": "78.79 %", "Outcome": "percentage of discharged patients", "Count": ""}, {"Intervention": "control", "Observation": "54.55 %", "Outcome": "percentage of discharged patients", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "ICU admission rate in the control group was significantly higher than the IFN group ( 66.66 % vs . 42.42 % , p = 0.04 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "control", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 33}, {"term": "IFN", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 77}], "Outcome": [{"term": "ICU admission rate", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}], "Observation": [{"term": "significantly higher", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 64}, {"term": "66.66 %", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 93}, {"term": "42.42", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 104}], "Count": []}, "Evidence Propositions": [{"Intervention": ["control", "IFN"], "Observation": "significantly higher", "Outcome": "ICU admission rate", "Count": ""}, {"Intervention": "control", "Observation": "66.66 %", "Outcome": "ICU admission rate", "Count": ""}, {"Intervention": "IFN", "Observation": "42.42", "Outcome": "ICU admission rate", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "The duration of hospitalization and ICU stay were not significantly different between the groups All-cause 28-day mortality was 6.06 % and 18.18 % in the IFN and control groups respectively ( p = 0.12 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the groups", "negation": "negated", "UMLS": {}, "start": 78, "end": 96}, {"term": "IFN", "negation": "negated", "UMLS": {}, "start": 154, "end": 157}, {"term": "control", "negation": "negated", "UMLS": {}, "start": 162, "end": 169}], "Outcome": [{"term": "duration of hospitalization and ICU stay", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 44}, {"term": "All-cause 28-day mortality", "negation": "negated", "UMLS": {}, "start": 97, "end": 123}], "Observation": [{"term": "significantly different", "negation": "negated", "UMLS": {}, "start": 54, "end": 77}, {"term": "6.06 %", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 134}, {"term": "18.18 %", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 146}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significantly different", "Outcome": "", "Count": ""}, {"Intervention": "between the groups", "Observation": "6.06 %", "Outcome": "duration of hospitalization and ICU stay", "Count": ""}, {"Intervention": "IFN", "Observation": "6.06 %", "Outcome": "duration of hospitalization and ICU stay", "Count": ""}, {"Intervention": "between the groups", "Observation": "18.18 %", "Outcome": "duration of hospitalization and ICU stay", "Count": ""}, {"Intervention": "control", "Observation": "18.18 %", "Outcome": "duration of hospitalization and ICU stay", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "IFN \u03b2-1b was effective in shortening the time to clinical improvement without serious adverse events in patients with severe COVID-19 .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "negated", "UMLS": {}, "start": 118, "end": 133}], "Intervention": [{"term": "IFN \u03b2-1b", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}], "Outcome": [{"term": "time to clinical improvement without serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 100}], "Observation": [{"term": "effective", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 22}, {"term": "shortening", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 36}], "Count": []}, "Evidence Propositions": [{"Intervention": "IFN \u03b2-1b", "Observation": "shortening", "Outcome": "time to clinical improvement without serious adverse events", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Furthermore , admission in ICU and need for invasive mechanical ventilation decreased following administration of IFN \u03b2-1b .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "IFN", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 117}], "Outcome": [{"term": "admission in ICU", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 30}, {"term": "need for invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 75}], "Observation": [{"term": "decreased", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 85}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Although 28-day mortality was lower in the IFN group , further randomized clinical trials with large sample size are needed for exact estimation of survival benefit of IFN \u03b2-1b .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [{"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 35}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier B.V . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}